Cristiane A Villela-Nogueira
Overview
Explore the profile of Cristiane A Villela-Nogueira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agoglia L, Peixoto H, Cardoso A, Barbosa L, Victer C, Carneiro S, et al.
An Bras Dermatol
. 2025 Mar;
PMID: 40082144
Background: Psoriasis (Pso) is an inflammatory skin disease associated with Metabolic Syndrome (MetS), Steatotic Liver Disease (SLD) and cardiovascular risk. However, the effect of anti-inflammatory therapy on cardiovascular risk is...
2.
Leite N, Villela-Nogueira C, Santos L, Cardoso C, Salles G
Diabetes Obes Metab
. 2025 Jan;
27(4):2024-2034.
PMID: 39822129
Background/aims: The prognostic importance of changes in vibration-controlled transient elastography (VCTE) parameters, liver stiffness measurement (LSM), and controlled attenuation parameter (CAP), in individuals with type 2 diabetes (T2D) and metabolic...
3.
Lai M, Dillon S, Gu X, Morhardt T, Xu Y, Chan N, et al.
Hepatol Commun
. 2024 Dec;
8(12).
PMID: 39621304
Background: Reliable, noninvasive tools to diagnose at-risk metabolic dysfunction-associated steatohepatitis (MASH) are urgently needed to improve management. We developed a risk stratification score incorporating proteomics-derived serum markers with clinical variables...
4.
Leite N, Cardoso C, Villela-Nogueira C, Salles G
Obesity (Silver Spring)
. 2024 Apr;
32(6):1210-1218.
PMID: 38664236
Objective: The objective of this study was to evaluate the effects of body weight variability (BWV) on the occurrence of adverse liver outcomes in individuals with type 2 diabetes (T2D)...
5.
Wajsbrot N, Leite N, Franca P, Lopes Cardoso C, Salles G, Villela-Nogueira C
Dig Dis Sci
. 2023 Dec;
69(2):634-642.
PMID: 38112841
Background & Aims: In non-alcoholic fatty liver disease (NAFLD), the influence of parental history of type 2 diabetes (T2D) allied to single nucleotide polymorphisms (SNPs) in the offspring is not...
6.
Cravo C, Villela-Nogueira C, Cardoso A, Perez R, Leite N
Liver Int
. 2023 Sep;
43(11):2571-2575.
PMID: 37752888
No abstract available.
7.
Barroso L, Salarini J, Leite N, Villela-Nogueira C, Davalos A, Carmo M, et al.
Clin Nutr ESPEN
. 2023 Sep;
57:117-125.
PMID: 37739645
Background & Aims: To date, no specific drugs are available for non-alcoholic fatty liver disease (NAFLD), though the effect of fish oil supplementation on improving fibrosis in patients with NAFLD...
8.
Tovo C, de Mattos A, Coral G, Sartori G, Nogueira L, Both G, et al.
World J Gastroenterol
. 2023 Jan;
29(2):343-356.
PMID: 36687125
Cirrhosis is an emerging major cause of the development of hepatocellular carcinoma (HCC), but in non-alcoholic fatty liver disease (NAFLD), up to 50% of patients with HCC had no clinical...
9.
Villela-Nogueira C, Ferraz M, Pessoa M, Souto F, Cancella Nabuco L, Coelho H, et al.
Ann Hepatol
. 2022 Oct;
28(1):100764.
PMID: 36182033
Introduction And Objectives: The Choosing Wisely (CW) initiative aims to improve daily practice supported by evidence concerning unnecessary medical tests, procedures, and treatments. This philosophy is essential in managing viral...
10.
Victor L, Perez R, Fernandes F, Piedade J, Villela-Nogueira C, Pereira G
Medicine (Baltimore)
. 2022 Sep;
101(35):e30097.
PMID: 36107613
Real-life data on the HCV treatment with direct-acting agents in patients with decompensated cirrhosis are scarce. Study to investigate the effectiveness and safety of sofosbuvir-containing regimens in a prospective cohort...